METFORMIN HYDROCHLORIDE PROLONGED RELEASE AND GLIMEPIRIDE TABLETS IP

About METFORMIN HYDROCHLORIDE PROLONGED RELEASE AND GLIMEPIRIDE TABLETS IP

Metformin Hydrochloride Prolonged Release and Glimepiride Tablets IP is a combination medication used to manage type 2 diabetes mellitus. Heres a detailed overview:

Composition & Classification:

• Metformin Hydrochloride (Prolonged Release):

  • Belongs to the biguanide class.

  • Works primarily by decreasing hepatic glucose production and increasing insulin sensitivity.

• Glimepiride:

  • Belongs to the sulfonylurea class.

  • Stimulates the pancreas to release more insulin.

Therapeutic Use:

• Indicated for: Type 2 Diabetes Mellitus (especially when diet, exercise, and single drug therapy are not adequate).

• Goal: To improve glycemic control and reduce the risk of complications from diabetes.

Mechanism of Action:

• Metformin:

  • Decreases liver glucose production.

  • Improves insulin sensitivity in peripheral tissues.

  • Delays intestinal glucose absorption.

• Glimepiride:

  • Stimulates pancreatic -cells to release insulin.

  • May also increase insulin sensitivity in tissues.

Dosage and Administration:

• Typically taken once daily with food to reduce gastrointestinal side effects (from metformin).

• Dosage depends on patients blood sugar levels and tolerance.

• Must be individualized under medical supervision.

Common Side Effects:

• Metformin:

  • Nausea, diarrhea, abdominal discomfort

  • Rare: lactic acidosis (serious)

• Glimepiride:

  • Hypoglycemia (low blood sugar)

  • Weight gain

  • Allergic skin reactions

Precautions:

• Renal impairment: Monitor kidney function before and during treatment.

• Liver disease: Use with caution.

• Alcohol: Increases risk of lactic acidosis and hypoglycemia.

• Not recommended in Type 1 diabetes or diabetic ketoacidosis.